EYPT

SEC source: 0001562180-23-005446 · primarydocument.xml · derivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Stock · 13,000 shares

Expires 2033-06-19

SEC source: 0001562180-23-005446 · primarydocument.xml · derivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,100

Underlying: Common Stock · 26,100 shares

Expires 2033-06-19

SEC source: 0001562180-23-005445 · primarydocument.xml · derivative · entry 1

Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,855

Underlying: Common Stock · 45,855 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.

F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.

SEC source: 0001562180-23-005443 · primarydocument.xml · derivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,855

Underlying: Common Stock · 45,855 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.

F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.

SEC source: 0001562180-23-005440 · primarydocument.xml · derivative · entry 1

Duker Jay S. · CIK 0001630864 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,380

Underlying: Common Stock · 62,380 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.

F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.

SEC source: 0001562180-23-004632 · primarydocument.xml · nonDerivative · entry 1

Liu Ye · CIK 0001840407 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Ocumension Therapeutics

Disclosed balance after: 3,010,721

F1 · kind: Sale of one share to test new broker

F2 · ownership.nature: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001562180-23-004579 · primarydocument.xml · derivative · entry 2

Elston George · CIK 0001429932 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires not disclosed

F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning May 25, 2024.

F2 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning May 25, 2024.

SEC source: 0001562180-23-004579 · primarydocument.xml · derivative · entry 1

Elston George · CIK 0001429932 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2033-05-24

F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at May 25th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-23-004580 · primarydocument.xml · derivative · entry 2

Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires not disclosed

F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning May 25, 2024.

F2 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning May 25, 2024.

SEC source: 0001562180-23-004580 · primarydocument.xml · derivative · entry 1

Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2033-05-24

F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at May 25th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 14

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-02-09

F14 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 75,000 shares of Common Stock of the Company.

F15 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 13

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Stock · 75,000 shares

Expires 2032-02-09

F14 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 75,000 shares of Common Stock of the Company.

F15 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 12

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 59,220

Underlying: Common Stock · 59,220 shares

Expires 2030-02-28

F12 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 59,220 shares of Common Stock of the Company.

F13 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 11

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,580

Underlying: Common Stock · 59,220 shares

Expires 2030-02-28

F12 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 59,220 shares of Common Stock of the Company.

F13 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 10

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 120,206

Underlying: Common Stock · 120,206 shares

Expires 2031-02-09

F10 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 120,206 shares of Common Stock of the Company.

F11 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 9

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,494

Underlying: Common Stock · 120,206 shares

Expires 2031-02-09

F10 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 120,206 shares of Common Stock of the Company.

F11 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 8

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 24,000

Underlying: Common Stock · 8,000 shares

Expires 2027-06-27

F8 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on December 15, 2017 and was fully vested at the time of the transfer,

F9 · derivative.exercise_date: The option vested and became exercisable in three equal annual installments beginning on June 27, 2018. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of June 27, 2020.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 7

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,000 shares

Expires 2027-06-27

F8 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on December 15, 2017 and was fully vested at the time of the transfer,

F9 · derivative.exercise_date: The option vested and became exercisable in three equal annual installments beginning on June 27, 2018. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of June 27, 2020.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 6

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 54,000

Underlying: Common Stock · 36,000 shares

Expires 2028-06-14

F6 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 14, 2018 and was fully vested at the time of the transfer.

F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments beginning on June 14, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of June 14, 2021.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 5

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,000 shares

Expires 2028-06-14

F6 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 14, 2018 and was fully vested at the time of the transfer.

F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments beginning on June 14, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of June 14, 2021.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 93,000

Underlying: Common Stock · 65,868 shares

Expires 2029-02-21

F4 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 21, 2019 and was fully vested at the time of the transfer

F5 · derivative.exercise_date: The option vests and becomes exercisable ratably in 48 monthly installments beginning on March 21, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of March 21,2023.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,868 shares

Expires 2029-02-21

F4 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 21, 2019 and was fully vested at the time of the transfer

F5 · derivative.exercise_date: The option vests and becomes exercisable ratably in 48 monthly installments beginning on March 21, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of March 21,2023.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 85,000

Underlying: Common Stock · 21,250 shares

Expires 2026-09-15

F1 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on December 12, 2016 and was exercisable for 85,000 shares of Common Stock of the Company. At the time of the transfer the option was fully vested.

F2 · derivative.exercise_date: The option vested and became exercisable in four equal annual installments beginning on September 15, 2017. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of September 15, 2020.

F3 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-23-004132 · primarydocument.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,250 shares

Expires 2026-09-15

F1 · kind: On May 11, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on December 12, 2016 and was exercisable for 85,000 shares of Common Stock of the Company. At the time of the transfer the option was fully vested.

F2 · derivative.exercise_date: The option vested and became exercisable in four equal annual installments beginning on September 15, 2017. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of September 15, 2020.

SEC source: 0001562180-23-001334 · primarydocument.xml · derivative · entry 2

ANDO GORAN · CIK 0001110748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date.

F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date.

SEC source: 0001562180-23-001334 · primarydocument.xml · nonDerivative · entry 1

ANDO GORAN · CIK 0001110748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-001332 · primarydocument.xml · derivative · entry 6

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,967

Underlying: Common Stock · 4,967 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

F4 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

SEC source: 0001562180-23-001332 · primarydocument.xml · derivative · entry 5

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units vest in three annual installments beginning February 9, 2023.

F3 · derivative.expiration_date: The restricted stock units vest in three annual installments beginning February 9, 2023.

SEC source: 0001562180-23-001332 · primarydocument.xml · nonDerivative · entry 4

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,133

F2 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.

SEC source: 0001562180-23-001332 · primarydocument.xml · nonDerivative · entry 3

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,606

F2 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.

SEC source: 0001562180-23-001332 · primarydocument.xml · nonDerivative · entry 2

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-001332 · primarydocument.xml · nonDerivative · entry 1

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 825 shares acquired on July 31, 2022 and 1,698 shares acquired on January 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

SEC source: 0001562180-23-001335 · primarydocument.xml · derivative · entry 2

Landis John B. · CIK 0001477283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date.

F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date.

SEC source: 0001562180-23-001335 · primarydocument.xml · nonDerivative · entry 1

Landis John B. · CIK 0001477283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-001330 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,534

Underlying: Common Stock · 17,533 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

SEC source: 0001562180-23-001330 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 20,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three annual installments beginning February 9, 2023.

F2 · derivative.expiration_date: The restricted stock units vest in three annual installments beginning February 9, 2023.

SEC source: 0001562180-23-001330 · primarydocument.xml · nonDerivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-001330 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,745 shares acquired on January 31, 2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

SEC source: 0001562180-23-001331 · primarydocument.xml · derivative · entry 4

Elston George · CIK 0001429932 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,967

Underlying: Common Stock · 4,967 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning February 9, 2023.

F2 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning February 9, 2023.

SEC source: 0001562180-23-001331 · primarydocument.xml · derivative · entry 3

Elston George · CIK 0001429932 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,667

Underlying: Common Stock · 5,833 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning February 9, 2023.

F2 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning February 9, 2023.

SEC source: 0001562180-23-001331 · primarydocument.xml · nonDerivative · entry 2

Elston George · CIK 0001429932 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,116

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-001331 · primarydocument.xml · nonDerivative · entry 1

Elston George · CIK 0001429932 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 887 shares acquired on 7/31/22 and 2,745 shares acquired on January 31, 2023, pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

SEC source: 0001562180-23-001336 · primarydocument.xml · derivative · entry 2

DICICCO WENDY F · CIK 0001225165 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date.

F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date.

SEC source: 0001562180-23-001336 · primarydocument.xml · nonDerivative · entry 1

DICICCO WENDY F · CIK 0001225165 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-001338 · primarydocument.xml · derivative · entry 2

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date.

F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date.

SEC source: 0001562180-23-001338 · primarydocument.xml · nonDerivative · entry 1

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-001337 · primarydocument.xml · derivative · entry 6

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,967

Underlying: Common Stock · 4,967 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

SEC source: 0001562180-23-001337 · primarydocument.xml · derivative · entry 5

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,667

Underlying: Common Stock · 5,833 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2023.

F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2023.

SEC source: 0001562180-23-001337 · primarydocument.xml · nonDerivative · entry 4

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,707

F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.

SEC source: 0001562180-23-001337 · primarydocument.xml · nonDerivative · entry 3

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,429

F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.